Interleukin levels and macrophagic density in periumbilical fat tissue in patients affected by moderate-to-severe psoriasis with metabolic syndrome, before and after etanercept treatment.
BACKGROUND
Psoriasis is a chronic inflammatory and immunological mediated skin disease characterized by epidermic proliferation, keratinocytes diversification disorder, excessive angiogenesis and immunological dysfunctions. Lately, the association of psoriasis with several comorbidities increased. Cardiovascular and metabolic disorders can be related to inflammatory conditions in which pro-inflammatory cytokines secreted by adipose tissue such as TNF-alpha increase. The aim of our study was to investigate the relation between abdominal adipose tissue inflammatory state and metabolic syndrome.


METHODS
Between January and June 2014 we selected 10 patients affected by moderate to severe psoriasis. Umbilical fat tissue biopsies were carried out before and after 24 weeks of treatment with TNF-alpha inhibitor (etanercept). Morphological parameters of macrophages were estimated using immunohistochemistry methods and hematoxilyn-eosin (H&E) coloration; IL-6 and TNF-alpha and IL1B were measured using molecular biology techniques.


RESULTS
After 24 weeks of treatment with TNF-alpha inhibitor (etanercept), a decrease of macrophages infiltration, inflammatory citokyne levels and gene expression were noticed.


CONCLUSIONS
The link between inflammatory status in umbilical fat tissue of patients affected by severe psoriasis and metabolic syndrome was confirmed.
Department of Dermatology, Macchi Hospital, Varese, Italy - alberico.motolese@asst-settelaghi.it.
Alberico
A
Motolese
Department of Dermatology, Macchi Hospital, Varese, Italy.
Valeria
V
Chiaravalloti
Department of Histopathology, Macchi Hospital, Varese, Italy.
Michele
M
Cerati
Department of Histopathology, Macchi Hospital, Varese, Italy.
Rita
R
Oldrini
Department of Dermatology, Macchi Hospital, Varese, Italy.
Federica
F
Mola
Department of Experimental and Clinical Biomedical Sciences, University of Insubria, Varese, Italy.
Alberto
A
Passi
D000273:Adipose Tissue / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D000068800:Etanercept / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D007378:Interleukins / Q000378:metabolism*; D008264:Macrophages / Q000378:metabolism*; D024821:Metabolic Syndrome / Q000276:immunology / Q000473:pathology*; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D012720:Severity of Illness Index; D014472:Umbilicus
D016207:Cytokines; D007166:Immunosuppressive Agents; D007378:Interleukins; D000068800:Etanercept